Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLU-808 in chronic inducible urticaria and chronic spontaneous urticaria
2024-520031-33-00Phase 2Completed
- Sponsor
- Blueprint Medicines
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in chronic inducible urticaria (CIndU) and chronic idiopathic urticaria (CIU) comparing BLU-808 with Placebo (2 arms). Primary endpoint: Overall safety profile. Started Sep 2025; status: completed.
02
Drugs
BLU-808
03
Conditions
chronic inducible urticaria (CIndU)chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2024-520031-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520031-33-00.